Myovant Sciences Ltd. reported earnings results for the second quarter and six months ended September 30, 2021. For the second quarter, the company reported revenue was USD 77.9 million. Net loss was USD 21.59 million compared to USD 67.06 million a year ago. Basic loss per share from continuing operations was USD 0.23 compared to USD 0.75 a year ago. For the six months, revenue was USD 118.97 million compared to USD 33.33 million a year ago. Net loss was USD 83.25 million compared to USD 99.92 million a year ago. Basic loss per share from continuing operations was USD 0.9 compared to USD 1.12 a year ago.